Terms: = Prostate cancer AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR
75 results:
1. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Piha-Paul SA; Xu B; Dumbrava EE; Fu S; Karp DD; Meric-Bernstam F; Hong DS; Rodon JA; Tsimberidou AM; Raghav K; Ajani JA; Conley AP; Mott F; Fan Y; Fan J; Peng P; Wang H; Ni S; Sun C; Qiang X; Levin WJ; Ngo B; Ru QC; Wu F; Javle MM
Oncologist; 2024 Apr; 29(4):e514-e525. PubMed ID: 38297981
[TBL] [Abstract] [Full Text] [Related]
2. Synthesis and Evaluation of Novel
Yao J; Fan M; Peng J; Luo H; Lu J
Mol Pharm; 2024 Feb; 21(2):895-903. PubMed ID: 38170629
[TBL] [Abstract] [Full Text] [Related]
3. Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across cancer Types.
Kasi PM; Lee JK; Pasquina LW; Decker B; Vanden Borre P; Pavlick DC; Allen JM; Parachoniak C; Quintanilha JCF; Graf RP; Schrock AB; Oxnard GR; Lovly CM; Tukachinsky H; Subbiah V
Clin Cancer Res; 2024 Feb; 30(4):836-848. PubMed ID: 38060240
[TBL] [Abstract] [Full Text] [Related]
4. FGF2 drives osteosarcoma metastasis through activating FGFR1-4 receptor pathway-mediated ICAM-1 expression.
Huang YC; Chen WC; Yu CL; Chang TK; I-Chin Wei A; Chang TM; Liu JF; Wang SW
Biochem Pharmacol; 2023 Dec; 218():115853. PubMed ID: 37832794
[TBL] [Abstract] [Full Text] [Related]
5. Taraxasterol suppresses the proliferation and tumor growth of androgen-independent prostate cancer cells through the fgfr2-PI3K/AKT signaling pathway.
Yang J; Xin C; Yin G; Li J
Sci Rep; 2023 Aug; 13(1):13072. PubMed ID: 37567936
[TBL] [Abstract] [Full Text] [Related]
6. Genome-wide analysis of somatic noncoding mutation patterns in cancer.
Dietlein F; Wang AB; Fagre C; Tang A; Besselink NJM; Cuppen E; Li C; Sunyaev SR; Neal JT; Van Allen EM
Science; 2022 Apr; 376(6589):eabg5601. PubMed ID: 35389777
[TBL] [Abstract] [Full Text] [Related]
7. Genetic and epigenetic bases of prostate tumor cell radioresistance.
Kutilin D
Klin Onkol; 2021; 34(3):220-234. PubMed ID: 34362257
[TBL] [Abstract] [Full Text] [Related]
8. Genetic and epigenetic bases of prostate tumor cell radioresistance.
Kutilin Denis
Ceska Gynekol; 2021; 86(3):220-234. PubMed ID: 34192880
[TBL] [Abstract] [Full Text] [Related]
9. Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in cancer Signaling.
Ferguson HR; Smith MP; Francavilla C
Cells; 2021 May; 10(5):. PubMed ID: 34068954
[TBL] [Abstract] [Full Text] [Related]
10. Transrectal ultrasound features and biopsy outcomes of transition PI-RADS 5.
Chung JH; Park BK
Acta Radiol; 2022 Apr; 63(4):559-565. PubMed ID: 34027681
[TBL] [Abstract] [Full Text] [Related]
11. Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma.
Bansal P; Dwivedi DK; Hatwal D; Sharma P; Gupta V; Goyal S; Maithani M
Anticancer Agents Med Chem; 2021; 21(18):2478-2486. PubMed ID: 33475078
[TBL] [Abstract] [Full Text] [Related]
12. Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With cancer.
Van Poznak CH; Unger JM; Darke AK; Moinpour C; Bagramian RA; Schubert MM; Hansen LK; Floyd JD; Dakhil SR; Lew DL; Wade JL; Fisch MJ; Henry NL; Hershman DL; Gralow J
JAMA Oncol; 2021 Feb; 7(2):246-254. PubMed ID: 33331905
[TBL] [Abstract] [Full Text] [Related]
13. Diagnosis and prognosis potential of four gene promoter hypermethylation in prostate cancer.
Li Y; Meng L; Shi T; Ren J; Deng Q
Cell Biol Int; 2021 Jan; 45(1):117-126. PubMed ID: 32991011
[TBL] [Abstract] [Full Text] [Related]
14. Erdafitinib: First Global Approval.
Markham A
Drugs; 2019 Jun; 79(9):1017-1021. PubMed ID: 31161538
[TBL] [Abstract] [Full Text] [Related]
15. Characterization of a KLK2-fgfr2 fusion gene in two cases of metastatic prostate cancer.
Krook MA; Barker H; Chen HZ; Reeser JW; Wing MR; Martin D; Smith AM; Dao T; Bonneville R; Samorodnitsky E; Miya J; Freud AG; Monk JP; Clinton SK; Roychowdhury S
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):624-632. PubMed ID: 31043681
[TBL] [Abstract] [Full Text] [Related]
16. Nuclear fgfr2 negatively regulates hypoxia-induced cell invasion in prostate cancer by interacting with HIF-1 and HIF-2.
Lee JE; Shin SH; Shin HW; Chun YS; Park JW
Sci Rep; 2019 Mar; 9(1):3480. PubMed ID: 30837551
[TBL] [Abstract] [Full Text] [Related]
17. When pitch adds to volume: coregulation of transcript diversity predicts gene function.
Cáceres A; González JR
BMC Genomics; 2018 Dec; 19(1):926. PubMed ID: 30545302
[TBL] [Abstract] [Full Text] [Related]
18. Ectopic fibroblast growth factor receptor 1 promotes inflammation by promoting nuclear factor-κB signaling in prostate cancer cells.
Wang C; Ke Y; Liu S; Pan S; Liu Z; Zhang H; Fan Z; Zhou C; Liu J; Wang F
J Biol Chem; 2018 Sep; 293(38):14839-14849. PubMed ID: 30093411
[TBL] [Abstract] [Full Text] [Related]
19. Paracrine Fibroblast Growth Factor Initiates Oncogenic Synergy with Epithelial FGFR/Src Transformation in prostate Tumor Progression.
Li Q; Ingram L; Kim S; Beharry Z; Cooper JA; Cai H
Neoplasia; 2018 Mar; 20(3):233-243. PubMed ID: 29444487
[TBL] [Abstract] [Full Text] [Related]
20. Phase II Study of Dovitinib in Patients with Castration-Resistant prostate cancer (KCSG-GU11-05).
Choi YJ; Kim HS; Park SH; Kim BS; Kim KH; Lee HJ; Song HS; Shin DY; Lee HY; Kim HG; Lee KH; Lee JL; Park KH
Cancer Res Treat; 2018 Oct; 50(4):1252-1259. PubMed ID: 29334610
[TBL] [Abstract] [Full Text] [Related]
[Next]